Nurix Therapeutics (NRIX) News Today $16.87 -0.17 (-1.00%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$16.58 -0.30 (-1.75%) As of 02/21/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Nurix Therapeutics: A Story To MonitorFebruary 18, 2025 | seekingalpha.comNurix Therapeutics (NRIX) to Release Quarterly Earnings on ThursdayFebruary 18, 2025 | americanbankingnews.comNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 14, 2025 | globenewswire.comSumitomo Mitsui Trust Group Inc. Raises Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 789,222 shares of the company's stock after acquiring an aFebruary 13, 2025 | marketbeat.comNurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on ThursdayNurix Therapeutics (NASDAQ:NRIX) will be releasing earnings on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from AnalystsNurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seventeen analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and sixteen have given aFebruary 5, 2025 | marketbeat.comNurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comNurix Therapeutics price target raised to $17 from $16 at Morgan StanleyFebruary 3, 2025 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)February 3, 2025 | markets.businessinsider.comNurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $17.00 at Morgan StanleyMorgan Stanley lifted their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research note on Monday.February 3, 2025 | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for NRIXNurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst R. Burns now forecasts that the company will pJanuary 31, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $55,798.35 in StockJanuary 31, 2025 | insidertrades.comNurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $55,798.35 in StockNurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares of the company's stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.January 30, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,690 SharesNurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.January 30, 2025 | marketbeat.comNurix Therapeutics' SWOT analysis: protein degrader stock's potentialJanuary 30, 2025 | msn.comPromising Clinical Developments and Strategic Collaborations Justify Buy Rating for Nurix TherapeuticsJanuary 30, 2025 | markets.businessinsider.comNurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory ShiftJanuary 30, 2025 | tipranks.comStifel raises Nurix stock price target to $36, maintains BuyJanuary 29, 2025 | msn.comRoyal Bank of Canada Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $27.00Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday.January 29, 2025 | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for Nurix Therapeutics (NASDAQ:NRIX) Stock PriceJPMorgan Chase & Co. reduced their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday.January 29, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Given New $36.00 Price Target at Stifel NicolausStifel Nicolaus increased their target price on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a "buy" rating in a research report on Wednesday.January 29, 2025 | marketbeat.comHC Wainwright Increases Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00HC Wainwright boosted their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Wednesday.January 29, 2025 | marketbeat.comNeedham & Company LLC Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00Needham & Company LLC lowered their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday.January 29, 2025 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)January 29, 2025 | markets.businessinsider.comNurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results, Misses Estimates By $0.08 EPSNurix Therapeutics (NASDAQ:NRIX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%.January 28, 2025 | marketbeat.comNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate UpdateJanuary 28, 2025 | globenewswire.comJPMorgan Chase & Co. Increases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)JPMorgan Chase & Co. increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 85.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 68,148 shares of the company's stock after buying an aJanuary 24, 2025 | marketbeat.comNurix Therapeutics appoints John Northcott as CCOJanuary 22, 2025 | markets.businessinsider.comNurix Therapeutics appoints new chief commercial officerJanuary 22, 2025 | msn.comNurix Therapeutics Announces Appointment of John Northcott as Chief Commercial OfficerJanuary 22, 2025 | globenewswire.comNurix Therapeutics: Strategic Pipeline Developments and Market Expansion Justify Buy RatingJanuary 22, 2025 | markets.businessinsider.comNurix Therapeutics (NASDAQ:NRIX) Given "Overweight" Rating at StephensStephens reaffirmed an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday.January 21, 2025 | marketbeat.comWe Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business GrowthJanuary 19, 2025 | finance.yahoo.comBarclays Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)January 16, 2025 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)January 14, 2025 | markets.businessinsider.comNurix Therapeutics sees cash runway into 1H27January 13, 2025 | markets.businessinsider.comNurix Therapeutics outlines 2025 goals, objectiveJanuary 13, 2025 | markets.businessinsider.comNurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune DiseasesJanuary 13, 2025 | markets.businessinsider.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seventeen brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation andJanuary 11, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Trading Down 7.1% - Here's WhyNurix Therapeutics (NASDAQ:NRIX) Stock Price Down 7.1% - Here's What HappenedJanuary 10, 2025 | marketbeat.comNurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein ModulationJanuary 9, 2025 | seekingalpha.comNurix Therapeutics (NASDAQ:NRIX) Stock Price Up 3.9% - Here's What HappenedNurix Therapeutics (NASDAQ:NRIX) Stock Price Up 3.9% - Still a Buy?January 8, 2025 | marketbeat.comNurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | finance.yahoo.comNurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comNurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For MeJanuary 5, 2025 | seekingalpha.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. grew its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 52.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,101 shares of the company's stock after buDecember 26, 2024 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC lifted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,448,040 shares of the company'sDecember 26, 2024 | marketbeat.comBarclays PLC Buys 56,190 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)Barclays PLC increased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 77.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 128,344 shares of the company's stockDecember 25, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Trading Down 3.2% - What's Next?Nurix Therapeutics (NASDAQ:NRIX) Trading Down 3.2% - Here's What HappenedDecember 24, 2024 | marketbeat.comJane Street Group LLC Has $3.54 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Jane Street Group LLC lowered its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 21.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 157,619 shares of the companyDecember 20, 2024 | marketbeat.com Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Media Mentions By Week NRIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRIX News Sentiment▼0.000.60▲Average Medical News Sentiment NRIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRIX Articles This Week▼25▲NRIX Articles Average Week Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VRNA News GRFS News TGTX News KRYS News SWTX News BHVN News RXRX News PTCT News OGN News RARE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRIX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRIX Stock Alerts